Terminated PHASE2 INTERVENTIONAL 2-arm NCT00932724

CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer (CY503C2)

Phase II Double-blind Placebo-controlled Trial of CY503 in Patients With Chemotherapy-refractory Metastatic Colorectal Cancer

Sponsor: Charite University, Berlin, Germany

Conditions Metastatic Colorectal Cancer

Interventions CY-503 Placebo

Updated 6 times since 2017 Last updated: Jul 9, 2013 Started: Jul 31, 2009 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The sponsor declared the early termination of the study due to poor recruitment of patients.

Other terminated trials from Charite University, Berlin, Germany

See all terminations from Charite University, Berlin, Germany

Other Metastatic Colorectal Cancer trials with similar outcome

Browse all Metastatic Colorectal Cancer trials

This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently terminated or withdrawn. Charite University, Berlin, Germany leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charite University, Berlin, Germany
ClinAssess GmbH
Cytavis Biopharma GmbH
Medical University Innsbruck

Data source: Cytavis Biopharma GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Altenburg, Germany , Amberg, Germany , Aschaffenburg, Germany , Bayreuth, Germany , Cologne, Germany , Dortmund, Germany , Dresden, Germany , Essen, Germany , Esslingen am Neckar, Germany , Frankfurt, Germany and 23 more locations